CELU
Price
$2.33
Change
+$0.01 (+0.43%)
Updated
Jan 23, 04:59 PM (EDT)
Capitalization
51.71M
PRAX
Price
$77.72
Change
-$1.87 (-2.35%)
Updated
Jan 23, 04:59 PM (EDT)
Capitalization
1.45B
47 days until earnings call
Ad is loading...

CELU vs PRAX

Header iconCELU vs PRAX Comparison
Open Charts CELU vs PRAXBanner chart's image
Celularity
Price$2.33
Change+$0.01 (+0.43%)
Volume$32.05K
Capitalization51.71M
Praxis Precision Medicines
Price$77.72
Change-$1.87 (-2.35%)
Volume$1.93K
Capitalization1.45B
CELU vs PRAX Comparison Chart
Loading...
CELU
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CELU vs. PRAX commentary
Jan 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CELU is a Hold and PRAX is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 24, 2025
Stock price -- (CELU: $2.30 vs. PRAX: $77.60)
Brand notoriety: CELU and PRAX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CELU: 39% vs. PRAX: 81%
Market capitalization -- CELU: $51.71M vs. PRAX: $1.45B
CELU [@Biotechnology] is valued at $51.71M. PRAX’s [@Biotechnology] market capitalization is $1.45B. The market cap for tickers in the [@Biotechnology] industry ranges from $360.23B to $0. The average market capitalization across the [@Biotechnology] industry is $2.41B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CELU’s FA Score shows that 0 FA rating(s) are green whilePRAX’s FA Score has 0 green FA rating(s).

  • CELU’s FA Score: 0 green, 5 red.
  • PRAX’s FA Score: 0 green, 5 red.
According to our system of comparison, CELU is a better buy in the long-term than PRAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CELU’s TA Score shows that 4 TA indicator(s) are bullish while PRAX’s TA Score has 2 bullish TA indicator(s).

  • CELU’s TA Score: 4 bullish, 2 bearish.
  • PRAX’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, CELU is a better buy in the short-term than PRAX.

Price Growth

CELU (@Biotechnology) experienced а +4.55% price change this week, while PRAX (@Biotechnology) price change was +10.46% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.04%. For the same industry, the average monthly price growth was +3.42%, and the average quarterly price growth was -1.05%.

Reported Earning Dates

CELU is expected to report earnings on May 14, 2024.

PRAX is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (+4.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRAX($1.45B) has a higher market cap than CELU($51.7M). CELU YTD gains are higher at: 10.577 vs. PRAX (0.832). CELU has higher annual earnings (EBITDA): -21.59M vs. PRAX (-163.59M). PRAX has more cash in the bank: 357M vs. CELU (133K). PRAX has less debt than CELU: PRAX (1.66M) vs CELU (69.1M). CELU has higher revenues than PRAX: CELU (48.2M) vs PRAX (1.61M).
CELUPRAXCELU / PRAX
Capitalization51.7M1.45B4%
EBITDA-21.59M-163.59M13%
Gain YTD10.5770.8321,272%
P/E RatioN/AN/A-
Revenue48.2M1.61M3,003%
Total Cash133K357M0%
Total Debt69.1M1.66M4,163%
TECHNICAL ANALYSIS
Technical Analysis
CELUPRAX
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 16 days ago
63%
Bearish Trend 16 days ago
88%
Momentum
ODDS (%)
Bearish Trend 16 days ago
64%
Bearish Trend 16 days ago
81%
MACD
ODDS (%)
Bullish Trend 16 days ago
69%
Bearish Trend 16 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 16 days ago
62%
Bearish Trend 16 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 16 days ago
78%
Bullish Trend 16 days ago
85%
Advances
ODDS (%)
Bullish Trend 21 days ago
75%
Bullish Trend 21 days ago
83%
Declines
ODDS (%)
Bearish Trend 16 days ago
78%
Bearish Trend 16 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 16 days ago
83%
N/A
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Ad is loading...
CELU
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VRDN18.760.41
+2.23%
Viridian Therapeutics
CSX33.670.43
+1.29%
CSX Corp
GGB2.930.02
+0.69%
Gerdau SA
SOHU12.810.01
+0.12%
Sohu.com Limited
OTLK2.04-0.05
-2.39%
Outlook Therapeutics

CELU and

Correlation & Price change

A.I.dvisor tells us that CELU and NVCT have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CELU and NVCT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CELU
1D Price
Change %
CELU100%
-0.86%
NVCT - CELU
28%
Poorly correlated
+5.25%
FATE - CELU
27%
Poorly correlated
N/A
PRAX - CELU
27%
Poorly correlated
-2.50%
RNAC - CELU
26%
Poorly correlated
+1.89%
SAGE - CELU
26%
Poorly correlated
+0.14%
More

PRAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRAX has been loosely correlated with INZY. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if PRAX jumps, then INZY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRAX
1D Price
Change %
PRAX100%
-2.50%
INZY - PRAX
39%
Loosely correlated
+1.54%
ZYME - PRAX
38%
Loosely correlated
+1.02%
STOK - PRAX
38%
Loosely correlated
+5.79%
XENE - PRAX
37%
Loosely correlated
+2.02%
SYRE - PRAX
37%
Loosely correlated
-0.05%
More